PMV Pharmaceuticals, Inc. (PMVP)
After hours:
| Previous close | 2.1000 |
| Open | 2.1100 |
| Bid | 2.0300 x 400 |
| Ask | 2.0700 x 100 |
| Day's range | 1.9750 - 2.1600 |
| 52-week range | 1.1750 - 9.7200 |
| Volume | |
| Avg. volume | 597,638 |
| Market cap | 104.945M |
| Beta (5Y monthly) | 1.55 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.4400 |
| Earnings date | 07 Aug 2024 - 12 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 8.75 |
GlobeNewswirePMV Pharmaceuticals Reports First Quarter 2024 Financial Results and Corporate Highlights
First patient dosed and continued enrollment in Phase 2 portion of the PYNNACLE trial evaluating rezatapopt as monotherapy in patients with TP53 Y220C and KRAS wild-type advanced solid tumors Phase 1 data of rezatapopt in advanced ovarian cancer featured in late-breaking oral presentation at 2024 SGO Annual Meeting on Women’s Cancer Cash, cash equivalents, and marketable securities of $213.1 million as of March 31, 2024, providing expected cash runway to end of 2026 PRINCETON, N.J., May 09, 2024
Simply Wall St.PMV Pharmaceuticals (NASDAQ:PMVP) Is In A Good Position To Deliver On Growth Plans
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
- GlobeNewswire
PMV Pharmaceuticals Announces First Patient Dosed in Global Tumor-Agnostic Phase 2 PYNNACLE Trial for Rezatapopt in TP53 Y220C-Positive Solid Tumors
Rezatapopt is a first-in-class precision oncology investigational therapy for patients with advanced solid tumors with a TP53 Y220C mutation and KRAS wild-type (WT)First patient dosed in Phase 2 portion of the PYNNACLE trial which will assess rezatapopt as monotherapy in patients with TP53 Y220C and KRAS WT advanced solid tumors PRINCETON, N.J., March 27, 2024 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of sm
